Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
Joachim Drevs(AstraZeneca (United Kingdom)), Clemens Unger(AstraZeneca (United Kingdom)), Ralph Strecker(Siemens Healthineers (Germany)), Ute Zirrgiebel(Johannes Gutenberg University Mainz), Helen Young(AstraZeneca (United Kingdom)), Patrizia Siegert(AstraZeneca (United Kingdom)), Thomas A. Puchalski(Dana-Farber Cancer Institute), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Hubert E. Blum, Jane Robertson(Cancer Research UK), K. Mross, Michael Medinger(University Hospital of Basel), Jan Harder(Hegau-Bodensee-Klinikum Singen), O. Saunders(AstraZeneca (United Kingdom))
Cited by 303
Related Papers
The Transjugular Intrahepatic Portosystemic Stent–Shunt Procedure for Refractory Ascites
|New England Journal of Medicine|1995|430
Analysis of CD161 expression on human CD8 <sup>+</sup> T cells defines a distinct functional subset with tissue-homing properties
|Proceedings of the National Academy of Sciences|2010|367
Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma
|Hepatology|2013|352
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Cytotoxic Metabolites from the Fungal Endophyte <i>Alternaria</i> sp. and Their Subsequent Detection in Its Host Plant <i>Polygonum senegalense</i>
|Journal of Natural Products|2008|252